Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590069 · ClinicalTrials.gov registry record · Phase 1
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
A Phase 1 study of Sarcoma and Metastatic Melanoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01590069: Active Phase 1 study of Sarcoma and Metastatic Melanoma, sponsored by M.D. Anderson Cancer Center.
NCT01590069 is a Phase 1 study of Sarcoma and Metastatic Melanoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01590069, a Phase 1 study of Sarcoma and Metastatic Melanoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs. Biological therapies, such as aerosolized aldesleukin, may stimulate or suppress the immune system in different ways and stop tumor cells from growing.
Primary Outcome
The dose escalation will be conducted via the accelerated titration method for the first 2 dose levels.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Aerosolized Aldesleukin
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2012-06-28 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
What the registry record for NCT01590069 still lists
NCT01590069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (92% lower).
The record links to 8 conditions, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01590069 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01590069 about?
NCT01590069 is a clinical study titled "Aerosolized Aldesleukin in Treating Patients With Lung Metastases". This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs. Biological therapies, such as aerosolized aldesleukin, may stimulate or suppress the immune syst...
What is the current status of trial NCT01590069?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2012-06-28. Estimated completion is 2026-04-30.
What conditions does trial NCT01590069 study?
This clinical trial studies the following conditions: Sarcoma, Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma.
What interventions are being tested in trial NCT01590069?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Aerosolized Aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT01590069?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01590069 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01590069's enrollment target sits among peer trials
70 54th of 122 higher than 67 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy